1ysn

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1ysn.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1ysn.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1ysn| PDB=1ysn | SCENE= }}
{{STRUCTURE_1ysn| PDB=1ysn | SCENE= }}
-
'''Solution structure of the anti-apoptotic protein Bcl-xL complexed with an acyl-sulfonamide-based ligand'''
+
===Solution structure of the anti-apoptotic protein Bcl-xL complexed with an acyl-sulfonamide-based ligand===
-
==Overview==
+
<!--
-
Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-X(L) expression correlates with chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anti-cancer therapeutics has been previously explored, but obtaining potent small-molecule inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction. Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumours, and produces cures in a high percentage of the mice.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15902208}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15902208 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15902208}}
==About this Structure==
==About this Structure==
-
1YSN is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YSN OCA].
+
1YSN is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YSN OCA].
==Reference==
==Reference==
Line 57: Line 61:
[[Category: Apoptosis]]
[[Category: Apoptosis]]
[[Category: Complex]]
[[Category: Complex]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 16:44:05 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 03:25:55 2008''

Revision as of 00:26, 28 July 2008

Template:STRUCTURE 1ysn

Solution structure of the anti-apoptotic protein Bcl-xL complexed with an acyl-sulfonamide-based ligand

Template:ABSTRACT PUBMED 15902208

About this Structure

1YSN is a Single protein structure of sequence from Homo sapiens. Full experimental information is available from OCA.

Reference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours., Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15. PMID:15902208

Page seeded by OCA on Mon Jul 28 03:25:55 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools